Newsroom
March 28, 2022
Structural racism, rather than disease, leads to inequities, authors write Contacts: Will Sansom, (210) 567-2579, sansom@uthscsa.edu Steven Lee, (210) 450-3823, lees22@uthscsa.edu SAN ANTONIO (March 28, 2022) — Black patients with cancer experienced significantly worse outcomes after COVID-19 diagnosis than non-Hispanic white cancer patients in a study published March 28 in JAMA Network Open. Investigators of […]
March 18, 2022
Contact: Will Sansom, (210) 567-2579, sansom@uthscsa.edu SAN ANTONIO (March 18, 2022) — Ruben A. Mesa, MD, FACP, professor of medicine and executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, testified on clinical trial diversity yesterday (March 17, 2022) before the House Committee on Energy and Commerce. The […]
March 10, 2022
An internationally recognized physician-scientist of Mays Cancer Center at UT Health San Antonio, together with SignalRx Pharmaceuticals Inc., have secured two National Cancer Institute business grants to further develop drugs on a pathway to first-in-human cancer clinical trials. The clinical translational researcher, Daruka Mahadevan, MD, PhD, division chief of hematology and medical oncology at UT […]
March 10, 2022
Contact: Steven Lee, 210-450-3823, lees22@uthscsa.edu SAN ANTONIO – An internationally recognized physician-scientist of Mays Cancer Center at UT Health San Antonio together with SignalRx Pharmaceuticals Inc. have secured two National Cancer Institute business grants to further develop drugs on a pathway to first-in-human cancer clinical trials. The clinical translational researcher, Daruka Mahadevan, MD, PhD, division […]
March 10, 2022
Only the most elite programs garner 3-star ratings from the Society of Thoracic Surgeons. Contact: Will Sansom, (210) 567-2579, sansom@uthscsa.edu SAN ANTONIO (March 10, 2022) — The UT Health San Antonio Department of Cardiothoracic Surgery has earned a distinguished three-star rating from the Society of Thoracic Surgeons (STS) for its patient care and lung and […]
March 3, 2022
The FDA has approved pacritinib for myelofibrosis patients with low platelet counts. Investigators at the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, played a lead role in gaining U.S. Food and Drug Administration approval of pacritinib to treat the chronic leukemia known as myelofibrosis. The FDA granted accelerated approval of the […]
